keyword
https://read.qxmd.com/read/38491799/cost-effectiveness-analysis-of-different-treatment-modalities-in-bcg-unresponsive-nmibc
#1
JOURNAL ARTICLE
Constantin Rieger, Jörg Schlüchtermann, Enno Storz, Lucas Kastner, David Pfister, Axel Heidenreich
OBJECTIVE: Radical cystectomy (RC) is the standard of care (SOC) in BCG-unresponsive NMIBC and is associated with a significant health-related quality-of-life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, and Hyperthermic Intravesical Chemotherapy (HIVEC) as salvage therapy options trying to increase the rate of bladder preservation. Here, we performed a Cost-Effectiveness-Analysis of those treatment modalities. PATIENTS AND METHODS: We developed a Markov model from a payer's perspective drawing on clinical data of single-arm trials testing intravesical gemcitabine/docetaxel and pembrolizumab in BCG-unresponsive NMIBC, as well as clinical data from patients receiving hyperthermic intravesical chemotherapy HIVEC (n = 29) as intravesical salvage chemotherapy at our uro-oncological centre in Cologne...
March 16, 2024: BJU International
https://read.qxmd.com/read/38473301/the-current-landscape-of-prostate-specific-membrane-antigen-psma-imaging-biomarkers-for-aggressive-prostate-cancer
#2
REVIEW
Haidar Al Saffar, David C Chen, Carlos Delgado, Jacob Ingvar, Michael S Hofman, Nathan Lawrentschuk, Marlon Perera, Declan G Murphy, Renu Eapen
The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and distant PCa, and its potential as a prognostic indicator for biochemical recurrence and overall survival. Additionally, we focused on the variability of PSMA's expression and its impact on personalised treatment, particularly the use of [177 Lu] Lu-PSMA-617 radioligand therapy...
February 26, 2024: Cancers
https://read.qxmd.com/read/38466861/cancer-centers-of-excellence-for-the-multidisciplinary-management-of-urologic-cancers-the-intersection-between-education-research-and-healthcare
#3
REVIEW
Daniel Andrés Nieva-Posso, Philippe E Spiess, Herney Andrés García-Perdomo
Urologic cancers are among the leading causes of morbidity and mortality in the world, representing more than 10% of the total number of new cancer cases worldwide. These complex diseases are linked to several issues related to their diagnosis, management, monitoring, and treatment - issues that require multidisciplinary solutions that encompass and manage patients as complex entities. In response to this, the so-called cancer centers of excellence (CCEs) emerged, defined as multidisciplinary institutions specialized in the diagnosis, management, monitoring, and treatment of specific diseases, including cancer...
March 1, 2024: Canadian Urological Association Journal
https://read.qxmd.com/read/38437876/complications-of-immuno-oncology-care-what-urologist-should-know
#4
REVIEW
Valentina Grajales, Alberto Martini, Neal D Shore
OBJECTIVES: To provide a practical review of immune-related adverse events (irAEs) that may be encountered in uro-oncology patients. PATIENTS AND METHODS: We conducted a literature review of studies reporting irAEs including articles published through September 2023 for uro-oncology patients and the potential relevancy for the practicing urologist. RESULTS: Immunotherapy has revolutionised cancer treatment, extending its impact to urological malignancies including for patients with urothelial, kidney, and prostate cancers...
March 4, 2024: BJU International
https://read.qxmd.com/read/38426242/definitions-outcomes-and-perspectives-for-oligometastatic-bladder-cancer-towards-a-standardized-terminology
#5
JOURNAL ARTICLE
Giorgio Calleris, Markus von Deimling, Claudia Kesch, Francesco Soria, Paolo Gontero, Guillaume Ploussard, Ekaterina Laukhtina, Benjamin Pradère
PURPOSE OF REVIEW: Oligometastatic (om) cancer is considered as a transitional state in between locally confined disease and widespread metastases, accessible to a multimodal treatment, combining systemic and local therapy. In urothelial bladder cancer (BCa), the definitions and the approaches to this condition are poorly standardised and mainly based on retrospective data. We aim to portray the framework for uro-oncologic terminology in omBCa and go through the latest evidence and the future perspectives...
March 1, 2024: Current Opinion in Urology
https://read.qxmd.com/read/38421452/improvements-in-urinary-symptoms-health-related-quality-of-life-and-psychosocial-distress-in-the-early-recovery-period-after-radical-cystectomy-and-urinary-diversion-in-842-german-bladder-cancer-patients-data-from-uro-oncological-rehabilitation
#6
JOURNAL ARTICLE
Henning Bahlburg, Karl Heinrich Tully, Peter Bach, Marius Cristian Butea-Bocu, Moritz Reike, Florian Roghmann, Joachim Noldus, Guido Müller
PURPOSE: This study aims to investigate urinary symptoms (continence and stoma care), health-related quality of life (HRQoL) and psychosocial distress (PD) in the early postoperative period after radical cystectomy (RC) and urinary diversion for ileal conduit (IC) and ileal neobladder (INB) to obtain a better basis for patient counseling. METHODS: Data for 842 bladder cancer patients, who underwent 3 weeks of inpatient rehabilitation (IR) after RC and urinary diversion (447 IC, 395 INB) between April 2018 and December 2019 were prospectively collected...
February 29, 2024: World Journal of Urology
https://read.qxmd.com/read/38418597/-palliative-surgery-for-metastatic-prostate-cancer
#7
REVIEW
Axel Heidenreich, Christian Bach, David Pfister
Androgen deprivation in combination with novel hormonal agents, docetaxel, or in combination with abiraterone/prednisone plus docetaxel or darolutamid plus docetaxel represent the standard therapeutic approach in metastatic hormone-sensitive prostate cancer (mHSPC). Patients with low-risk prostate cancer also benefit from additional radiation therapy or radical prostatectomy in terms of progression-free and overall survival. Despite favorable response rates, basically all patients will develop castration resistant prostate cancer (CRPC) within 2...
February 28, 2024: Urologie
https://read.qxmd.com/read/38410103/time-to-strategy-failure-and-treatment-beyond-progression-in-pretreated-metastatic-renal-cell-carcinoma-patients-receiving-nivolumab-post-hoc-analysis-of-the-meet-uro-15-study
#8
JOURNAL ARTICLE
Veronica Murianni, Alessio Signori, Sebastiano Buti, Sara Elena Rebuzzi, Davide Bimbatti, Ugo De Giorgi, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Cristina Masini, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Veronica Mollica, Mariella Sorarù, Marianna Tudini, Veronica Prati, Andrea Malgeri, Francesco Atzori, Marilena Di Napoli, Orazio Caffo, Massimiliano Spada, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Helga Lipari, Giandomenico Roviello, Fabio Catalano, Alessandra Damassi, Malvina Cremante, Pasquale Rescigno, Giuseppe Fornarini, Giuseppe Luigi Banna
BACKGROUND: Immunotherapies exhibit peculiar cancer response patterns in contrast to chemotherapy and targeted therapy. Some patients experience disease response after initial progression or durable responses after treatment interruption. In clinical practice, immune checkpoint inhibitors may be continued after radiological progression if clinical benefit is observed. As a result, estimating progression-free survival (PFS) based on the first disease progression may not accurately reflect the actual benefit of immunotherapy...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38371197/validation-of-non-muscle-invasive-bladder-cancer-risk-stratification-updated-in-the-2021-european-association-of-urology-guidelines
#9
JOURNAL ARTICLE
Makito Miyake, Hiroshi Kitamura, Nobutaka Nishimura, Tatsuki Miyamoto, Tomonori Nakahama, Tomomi Fujii, Hiroaki Matsumoto, Hideyasu Matsuyama, Masaya Yonemori, Hideki Enokida, Rikiya Taoka, Takashi Kobayashi, Takahiro Kojima, Yoshiyuki Matsui, Naotaka Nishiyama, Hiroyuki Nishiyama, Kiyohide Fujimoto
OBJECTIVE: The objective of this study is to validate the predictive ability of the 2021 European Association of Urology (EAU) risk model compared to that of existing risk models, including the 2019 EAU model and risk scoring tables of the European Organization for Research and Treatment of Cancer, Club Urologico Espanol de Tratamiento Oncologico, and Japanese Nishinihon Uro-oncology Extensive Collaboration Group. PATIENTS AND METHODS: This retrospective multi-institutional database study included two cohorts-3024 patients receiving intravesical bacillus Calmette-Guerin (BCG) treatment (BCG cohort) and 789 patients not receiving BCG treatment (non-BCG cohort)...
March 2024: BJUI compass
https://read.qxmd.com/read/38357197/addressing-the-risk-and-management-of-cardiometabolic-complications-in-prostate-cancer-patients-on-androgen-deprivation-therapy-and-androgen-receptor-axis-targeted-therapy-consensus-statements-from-the-hong-kong-urological-association-and-the-hong-kong-society
#10
REVIEW
Darren M C Poon, Guang-Ming Tan, Kuen Chan, Marco T Y Chan, Tim-Wai Chan, Raymond W M Kan, Martin H C Lam, Clarence L H Leung, Kenneth C W Wong, Kevin K H Kam, Chi-Fai Ng, Peter K F Chiu
BACKGROUND: Androgen deprivation therapy (ADT) is the foundational treatment for metastatic prostate cancer (PCa). Androgen receptor (AR) axis-targeted therapies are a new standard of care for advanced PCa. Although these agents have significantly improved patient survival, the suppression of testosterone is associated with an increased risk of cardiometabolic syndrome. This highlights the urgency of multidisciplinary efforts to address the cardiometabolic risk of anticancer treatment in men with PCa...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38270604/-lymph-node-metastatic-penile-cancer-a%C3%A2-challenge-in-uro-oncology-guideline-conform-treatment
#11
REVIEW
D L Dräger, J Nolting, M Pohla, O W Hakenberg
Penile squamous cell carcinoma is a rare, highly aggressive cancer of older men. The metastatic stage has significant therapeutic and prognostic features. Treatment of penile cancer is significantly influenced by the operation, in which an R0 situation must be achieved to ensure a realistic chance of cure. Other local therapeutic procedures such as radiotherapy are often of secondary importance. Neoadjuvant and adjuvant chemotherapy are relevant components of multimodal therapy. Post-therapeutically, patients require lifelong, risk-adapted follow-up care...
January 25, 2024: Urologie
https://read.qxmd.com/read/38254807/how-to-integrate-prostate-cancer-biomarkers-in-urology-clinical-practice-an-update
#12
REVIEW
Catalin Baston, Adrian Preda, Alexandru Iordache, Vlad Olaru, Cristian Surcel, Ioanel Sinescu, Constantin Gingu
Nowadays, the management of prostate cancer has become more and more challenging due to the increasing number of available treatment options, therapeutic agents, and our understanding of its carcinogenesis and disease progression. Moreover, currently available risk stratification systems used to facilitate clinical decision-making have limitations, particularly in providing a personalized and patient-centered management strategy. Although prognosis and prostate cancer-specific survival have improved in recent years, the heterogenous behavior of the disease among patients included in the same risk prognostic group negatively impacts not only our clinical decision-making but also oncological outcomes, irrespective of the treatment strategy...
January 11, 2024: Cancers
https://read.qxmd.com/read/38232756/-palliative-urologic-surgery-for-metastatic-prostate-cancer-what-needs-to-be-considered-in-the-future
#13
JOURNAL ARTICLE
Axel Heidenreich, Christian Bach, David Pfister
Androgen deprivation in combination with novel hormonal agents, docetaxel or the combination of abiraterone/prednisone plus docetaxel or darolutamide plus docetaxel represent the standard therapeutic approach in metastatic hormone-sensitive prostate cancer (mHSPC). Patients with low-risk prostate cancer also benefit from additional radiation therapy or radical prostatectomy in terms of progression-free and overall survival. Despite favourable response rates, basically all patients will develop castration-resistant prostate cancer (CRPC) within 2...
January 17, 2024: Aktuelle Urologie
https://read.qxmd.com/read/38190056/prognostic-impact-of-preoperative-thrombocytosis-on-recurrence-free-survival-in-patients-with-upper-tract-urothelial-carcinoma
#14
JOURNAL ARTICLE
Bogomir Milojevic, Aleksandar Janicic, Isidora Grozdic Milojevic, Nikola Grubor, Uros Bumbasirevic, Milan Radovanovic, Djordje Radisavcevic, Darko Jovanovic, Milan Sretenovic, Otas Durutovic, Sandra Sipetic Grujicic
BACKGROUND: The aim of this work was to evaluate the prognostic potential of preoperative thrombocytosis for recurrence-free survival (RFS) and cancer-specific survival (CSS) among patients subjected to radical nephroureterectomy (RNU) due to UTUC. PATIENTS AND METHODS: Analytical cohort was composed of a single-center series of 405 patients treated between January 1999 and December 2020. Thrombocytosis was defined as a platelet count exceeding the threshold value of 400 × 109 per L...
January 8, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38180677/surgical-management-of-primary-anorectal-melanoma-is-less-more
#15
JOURNAL ARTICLE
Michael G Fadel, Hesham S Mohamed, Justin Weir, Andrew J Hayes, James Larkin, Myles J Smith
PURPOSE: Ano-uro-genital (AUG) Mucosal Melanoma UK guidelines recommended a less radical surgical strategy for anorectal melanoma (ARM) where possible. We report our experience of ARM consistent with that approach including clinical presentation, intervention undertaken and prognosis. METHODS: We present a retrospective study of 15 consecutive patients with ARM surgically treated between November 2014 and April 2023. Patients were divided into the two surgery types: wide local excision (WLE, n = 9) and abdominoperineal resection (APR, n = 6)...
January 5, 2024: Journal of Gastrointestinal Cancer
https://read.qxmd.com/read/38179033/a-prospective-study-on-single-port-versus-multiport-patient-reported-surgical-outcomes
#16
JOURNAL ARTICLE
Luca A Morgantini, Ahmad Alzein, Arthi Bharadwaj, Matthew S Del Pino, Erin Egan, Ashwin Ganesh, John Smith, Simone Crivellaro
INTRODUCTION: We sought to determine potential patient reported advantages of the da Vinci single-port (SP) robotic system for urological procedures compared with the previous model, the da Vinci multiport (MP) system. The SP model utilizes a single 30 to 40 mm incision rather than multiple 5 to 22 mm incisions. This project aims to prospectively investigate the impact of the novel SP system on patient reported cosmetic and psychometric surgical outcomes. METHODS: We conducted a prospective study of patients who underwent uro-oncologic surgery by three urologists at the University of Illinois Chicago from April to November 2021...
January 2024: BJUI compass
https://read.qxmd.com/read/38169055/variant-histology-is-associated-with-more-non-urothelial-tract-recurrence-but-less-intravesical-recurrence-for-upper-tract-urothelial-carcinoma-after-radical-nephroureterectomy
#17
JOURNAL ARTICLE
Tsung Yu Yu, Hung Jen Wang, Min Tse Sung, Yao Chi Chuang, Yen Ta Chen, Yuan Tso Cheng, Chih Hsiung Kang, Hui Ying Liu, Yin Lun Chang, Hao Lun Luo
PURPOSE: To investigate the prognostic impact of variant histology (VH) on oncological outcomes in patients with upper urinary tract urothelial carcinoma (UTUC) who had undergone radical nephroureterectomy (RNU). PATIENTS AND METHODS: A total of 1239 patients with clinically localized UTUC who underwent RNU at a single institution between January 2005 and June 2020 were included. The VH was reviewed by a uro-pathologist at our institution. The Cox regression model was used to perform multivariate analysis, including VH and other established prognostic factors for post-RNU oncological outcomes (intravesical recurrence [IVR], non-urothelial recurrence, and cancer-specific death)...
January 2, 2024: International Journal of Urology: Official Journal of the Japanese Urological Association
https://read.qxmd.com/read/38072680/the-evolution-of-pet-imaging-in-renal-bladder-upper-urinary-tract-urothelial-testicular-and-penile-carcinoma-today-s-impact-tomorrow-s-potential
#18
REVIEW
Luca Urso, Matteo Bauckneht, Domenico Albano, Sotirios Chondrogiannis, Gaia Grassetto, Francesco Lanfranchi, Francesco Dondi, Giuseppe Fornarini, Massimo Lazzeri, Laura Evangelista
INTRODUCTION: The advancement of hybrid PET/CT or PET/MRI imaging for non-prostate genitourinary cancers has not experienced the rapid progress of prostate cancer. Nevertheless, these neoplasms are aggressive and reliable imaging plays a pivotal role in enhancing patients' quality of life and prognosis. AREAS COVERED: the main evidence regarding [18 F]FDG and non-[18 F]FDG PET/CT or PET/MRI in non-prostate uro-oncological malignancies are summarized and discussed...
December 10, 2023: Expert Review of Medical Devices
https://read.qxmd.com/read/38045560/framework-for-a-living-systematic-review-and-meta-analysis-for-the-surgical-treatment-of-bladder-cancer-introducing-eviglance-to-urology
#19
JOURNAL ARTICLE
Victoria L S Wieland, Daniel Uysal, Pascal Probst, Maurizio Grilli, Caelán M Haney, Marie A Sidoti Abate, Luisa Egen, Manuel Neuberger, Giovanni E Cacciamani, Maximilian C Kriegmair, Maurice S Michel, Karl-Friedrich Kowalewski
BACKGROUND: Knowledge of current and ongoing studies is critical for identifying research gaps and enabling evidence-based decisions for individualized treatment. However, the increasing number of scientific publications poses challenges for healthcare providers and patients in all medical fields to stay updated with the latest evidence. To overcome these barriers, we aim to develop a living systematic review and open-access online evidence map of surgical therapy for bladder cancer (BC), including meta-analyses...
October 2023: International journal of surgery protocols
https://read.qxmd.com/read/38038411/digital-health-innovations-in-urology-telemedicine-wearables-and-mobile-applications-a-systematic-review-of-literature
#20
JOURNAL ARTICLE
Nithesh Naik, Ali Talyshinskii, Jens Rassweiler, B M Zeeshan Hameed, Bhaskar K Somani
PURPOSE OF REVIEW: There are enough publications on the use of telemedicine, wearable devices, and mobile applications in urology; however, their collective impact on urological care has not been adequately studied. This review seeks to address this deficiency by providing a descriptive analysis of the recent use of telemedicine, wearable technology, and mobile applications in urology as well as elucidating their associated challenges. RECENT FINDINGS: There are studies that were dedicated to the use of telemedicine, wearables, and mobile apps in urology according to inclusion criteria, respectively...
December 4, 2023: Current Opinion in Urology
keyword
keyword
72641
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.